Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1999-05-01

AUTHORS

Michael J. McCluskie, Cynthia L. Brazolot Millan, Robert A. Gramzinski, Harriet L. Robinson, Joseph C. Santoro, James T. Fuller, Georg Widera, Joel R. Haynes, Robert H. Purcell, Heather L. Davis

ABSTRACT

BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 µg) was compared to ID and IM (100 µg) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 µg at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 µg by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required. More... »

PAGES

287-300

Journal

TITLE

Molecular Medicine

ISSUE

5

VOLUME

5

Related Patents

  • Oligodeoxynucleotide And Its Use To Induce An Immune Response
  • Vaccines For Blocking Transmission Of Plasmodium Vivax
  • Tuberculosis Therapy; Anticancer Agents
  • Which Contains A Cytosine, Guanine Dinucleotide Sequence And Stimulates (For Example, Has A Mitogenic Effect) Vertebrate Immune Cells
  • Vaccine Comprising A Polynucleotide Encoding An Antigen Recognized By A Cd4+ Helper T-Cell And A Polynucleotide Encoding A Tumor Specific Or Associated Antigen Recognized By A Cd8+ Ctl
  • Delivery Of Therapeutic Agents By Gene Therapy
  • Induction Of Mucosal Tolerance To Antigens
  • Methods And Compositions For Treating Prostate Cancer Using Dna Vaccines
  • Method Of Epitope Discovery
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Measles Vaccine Vectors And Methods Of Use
  • Delivering Dna Encoding Peptide Or Protein Into Cell Of Mammal; Administering Ionizable Transition Metal Compound Enhancer; Gene Expression
  • Suppression Of Malignancy Utilizing Ribonucleotide Reductase R1
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Superior Molecular Vaccine Linking The Translocation Domain Of A Bacterial Toxin To An Antigen
  • For Treatment Of Atopic Conditions (Dermatitis, Allergies) And Influenza Virus; Point Mutations
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Hiv-1 South African Subtype C Env Proteins
  • Pharmaceutically Purified Intact Bacterial Minicells
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Compositions And Methods For Administering Borrelia Dna
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Immunogenic Compositions For Protection Against Chlamydial Infection
  • Methods For The Early Diagnosis Of Ovarian Cancer
  • Automatic Baroreflex Modulation Responsive To Adverse Event
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Methods Of Using Immunostimulatory Nucleic Acid Molecules To Treat Allergic Conditions
  • Treating Inflammatory Bowel Disease In Humans; Obtain Human, Administer Drug, Monitor For Reduction In Side Effects From Gastrointestinal Disorder
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs; Adjuvant
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigents Using Genetically Modified Lactobacillus
  • Use Of Immunopotentiating Sequences For Inducing Immune Response
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Method To Enhance An Immune Response Of Nucleic Acid Vaccination
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Pharmaceutically Compatible Method For Purifying Intact Bacterial Minicells
  • Molecular Vaccine Linking An Endoplasmic Reticulum Chaperone Polypeptide To An Antigen
  • Administering To A Human, A Naked Dna Comprising A Dna Fragment Encoding A Polypeptide Consisting Essentially Of A Portion Of An Immunogenic Dust Mite Antigen; Fragment Is Amplified By A Primer Pair; Dermatophagoides; Antiallergens
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Dna Vaccine Enhancement With Mhc Class Ii Activators
  • Compositions And Methods For Delivery Of Genetic Material
  • Light Emitting Microorganisms And Cells For Diagnosis And Therapy Of Tumors
  • Immunostimulatory Nucleic Acid Molecules
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Wherein Dna Vaccine Comprises Plasmid Containing Nucleotide Sequence Encoding An Immunogen Of A Pathogen Of Bovine Or Porcine, Under Conditions Allowing The In Vivo Expression Of This Sequence, And A Cationic Lipid Ammonium Salt
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Dna Vaccines And Methods For The Prevention Of Transplantation Rejection
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Forming Densified Nucleic Acid Gene Material Without Biolistic Core Carrier For Transdermal Delivery Needleless Injection
  • Mycobacterial Disease, Malaria, Leishmaniasis, Toxoplasmosis, Schistosomiasis And Clonorchiasis; Antiallergens; Asthma
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Lead Electrode Incorporating Extracellular Matrix
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs
  • Aids Virus Vaccines Using Sendai Virus Vector
  • Microorganisms For Therapy
  • Antisense Inhibition Of Rad51
  • Delivery Of Therapeutic Gene Products By Intestinal Cell Expression
  • Epicardial Patch Including Isolated Extracellular Matrix With Pacing Electrodes
  • Light Emitting Microorganisms And Cells For Diagnosis And Therapy Of Diseases Associated With Wounded Or Inflamed Tissue
  • Immunostimulatory Nucleic Acid Molecules
  • Immunostimulatory Nucleic Acids
  • Superior Molecular Vaccine Linking The Translocation Domain Of A Bacterial Toxin To An Antigen
  • Induces Production Of A Cytokine Or Activates Dendritic Cells, Natural Killer Cells And Monocytes; Autoimmune Disorders; Vaccine
  • Methods For Genetic Immunization
  • Immunogenic Composition Comprising Bacterial Or Viral Vector, Antigen And Toxins; Escherichia And Baculovirus; Vaccines
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Recombinant, Thymidylate Synthase Defective, Lactococcus Comprising Heterologous Interleukin-10 Gene For Use As Gene Therapeutic Tool In Treatment Of Inflammatory Bowel Disease
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Expression Cassette Generated From These Sequences; Generating An Immune Response In A Subject
  • Use Of Cpg Oligodeoxynucleotides To Induce Epithelial Cell Growth
  • Extraneous Dna Sequence That Facilitates Hantavirus Gene Expression
  • Microorganisms For Therapy
  • Antitumoral Composition Based On Immunogenic Polypeptide With Modified Cell Location
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Composition And Method For Inhibiting Tumor Cell Growth
  • Adjuvant Preparation For The Induction Of Specific Immunity
  • Induce Immunology Response; Antiallergens; Bioavailability; Autoimmune Disease, Anticancer Agents, Antiallergens
  • Use Of Sterically Stabilized Cationic Liposomes To Efficiently Deliver Cpg Oligonucleotides In Vivo
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Prophylactic And Therapeutic Immunization Against Protozoan Infection And Disease
  • Pharmaceutical Compositions Comprising Purified Intact Bacterial Minicells
  • Modified Vaccinia Virus Strains For Use In Diagnostic And Therapeutic Methods
  • Expression Of Hiv Polypeptides And Production Of Virus-Like Particles
  • Administering An Adenovirus Expression Vector, Expressing A Protein On Cancer Cells For Treating Ovarian Cancer, Cervical Cancer, Stomach Cancer And Lung Cancer
  • Vagus Nerve Stimulation Responsive To A Tachycardia Precursor
  • Treatment And Prevention Of Neurodegenerative Diseases Using Gene Therapy
  • Malaria Vaccine And Methods Thereof Based Upon Novel Antigenic Domain Of Plasmodium Falciparum
  • Synergistic Mixtures; Hepatitis Virus
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigens Using Genetically Modified Lactococcus
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • Method Of Intranasal Gene Transfer For Protection Against Respiratory Infection
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Polynucleotide Composition, Method Of Preparation, And Use Thereof
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Comprises Therapeutic Polypeptide For Prevention And Treatment Of Mycobacterial Infections, Cancers And Immunological Disorders Gene And Immunotherapy
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • Microorganisms For Therapy
  • For Generating An Immune Response In A Subject; Synthetic Expression Cassettes Generated From These And Other Hiv Sequences; Vaccines; Immunogenic Hiv Gag Polypeptide
  • Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • Immunogens Comprising Plasmid Codes For Open Reading Frames Porcine Circovirus(Pcv) And Adjuvants Comprising Cationic Lipids; Immunology
  • Anti-Cancer Dna Vaccine Employing Plasmids Encoding Signal Sequence, Mutant Oncoprotein Antigen, And Heat Shock Protein
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Immobilized Vaccine; Gene Therapy
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Immunostimulatory Nucleic Acid Molecules
  • Contacting The Tumor With A Cytokine, Provided That Said Cytokine Is Not Interleukin-7 Or Tumor Necrosis Factor- Alpha, Or Administering At A Site Other Than The Tumor A Cytokine And A Tumor Antigen.
  • Nucleotide Sequences Coding Polypeptide For Use In The Treatment And Prevention Of Immunological Defects And Mycobacterial Infections; Bactericides
  • A Recombinant Lister Vaccinia Virus, Comprising A Modified Thymidine Kinase Gene, A Modified Hemagglutinin Gene, And A Modified F3gene Or Locus, Each Gene Or Locus Is Denactivated; The Virus Comprises Heterologous Nucleic Acid Encoding A Gene; Antitumor,Carcinogenic, -Proliferative Agents; Nontoxic
  • Baculovirus Expressing The Exogenous Nucleotide Sequence Porcine Circovirus-B (Pcvb) Open Reading Frame 2; Transformed Host Cells For Expressing Immunogenic Protein For Protecting Pigs Including Pregnant Pigs
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Nucleic Acid Compositions For Stimulating Immune Responses
  • Using Transition Metal Compound Promoter
  • Developing Genetic Vaccines To Prevent Trypanosoma Infections; Antiprotozoa Agents; Parasiticides
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Measles Vaccine Vectors And Methods Of Use
  • Polynucleotides Encoding Antigenic Hiv Type C Polypeptides, Polypeptides And Uses Thereof
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Include Recombinant Expression Constructs Containing Nucleic Acids Encoding Target Cell Surface Receptor Antigen And One Or More Immune Response Altering Molecules, Or The Expressed Products Themselves
  • Pcv2b Divergent Vaccine Composition And Methods Of Use
  • Microorganisms For Therapy
  • Defective Expression Of The Gamma 34.5 Gene And The Ribonucleotide Reductase Gene
  • Vectors And Methods For Immunization Or Therapeutic Protocols
  • For Inhibiting Neoplastic Cell Growth In A Human Or Mouse
  • Nucleic Acid Compositions For Stimulating Immune Responses
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Methods And Products For Inducing Mucosal Immunity
  • Allogeneic Cancer Cell-Based Immunotherapy
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Microorganisms For Therapy
  • Incubating Monocytes In Nutrient Broth Comprising Interleukins, Cytokine And Modified Nucleotide Sequences; Propagate Cells; Recover Antigen-Presenting Dendritic Cell, Contact With T-Lymphocyte
  • Treatment Of Immune Disease By Mucosal Delivery Of Antigens Using Genetically Modified Lactococcus
  • Nucleotide Vector Vaccine For Immunization Against Hepatitis
  • Induction Of Mucosal Tolerance To Antigens
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Immunostimulatory Sequence Oligonucleotides And Methods Of Using The Same
  • Administering To A Mammal A B Lymphocyte Chemoattractant (Blc) Or A Polynucleotide Encoding A Blc, And A Plasmid Containing Single Promoter Derived From The Virus Linked To Sequence Encoding Viral Immonogen To Enhance Immune Response
  • Polynucleotides Encoding Antigenic Hiv Type B Polypeptides, Polypeptides, And Uses Thereof
  • Expression Vectors Encoding Epitopes Of Target-Associated Antigens And Methods For Their Design
  • Vaccine
  • Therapeutic Compounds And Methods
  • Use Of Cpg Oligodeoxynucleotides To Induce Angiogenesis
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Microorganisms For Therapy
  • Vaccines Comprising An Immunostimulatory Peptide And An Immunostimulatory Oligodeoxynucleic Acid Molecule
  • Induction Of Mucosal Tolerance To Antigens
  • For Generating An Immune Response In A Subject
  • Method To Enhance An Immune Response Of Nucleic Acid Vaccination
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Multicomponent Vaccine; Immunogenic Polypeptide That Contains A Membrane Translocating Sequence, To Facilitate Introduction Of The Polypeptide Into The Mammalian Cell And Subsequent Stimulation Of The Cell-Mediated Immune Response; Chagas' Disease
  • Microorganisms For Therapy
  • Circovirus Sequences Associated With Piglet Weight Loss Disease (Pwd)
  • Rna Interference That Blocks Expression Of Pro-Apoptotic Proteins Potentiates Immunity Induced By Dna And Transfected Dendritic Cell Vaccines
  • Administering At Or Around The Solid Tumor An Expressible Nucleic Acid Encoding Interleukin-3, And Providing A Tumor Antigen, Then Treating The Tumor With Radiotherapy
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/bf03402065

    DOI

    http://dx.doi.org/10.1007/bf03402065

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1074485462

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/10390545


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Chemical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medicinal and Biomolecular Chemistry", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Cutaneous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Intranasal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Administration, Oral", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibody Formation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hepatitis B Surface Antigens", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hepatitis B Vaccines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunity, Cellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intramuscular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Injections, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Macaca mulatta", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice, Inbred BALB C", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Predictive Value of Tests", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes, Cytotoxic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vaccines, DNA", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.28046.38", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
                "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "McCluskie", 
            "givenName": "Michael J.", 
            "id": "sg:person.01337224357.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337224357.57"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.412687.e", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Millan", 
            "givenName": "Cynthia L. Brazolot", 
            "id": "sg:person.014200716477.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200716477.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA", 
              "id": "http://www.grid.ac/institutes/grid.415913.b", 
              "name": [
                "Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gramzinski", 
            "givenName": "Robert A.", 
            "id": "sg:person.01040316565.93", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040316565.93"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.168645.8", 
              "name": [
                "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Robinson", 
            "givenName": "Harriet L.", 
            "id": "sg:person.01350227236.96", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350227236.96"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.168645.8", 
              "name": [
                "Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Santoro", 
            "givenName": "Joseph C.", 
            "id": "sg:person.01362275224.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362275224.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fuller", 
            "givenName": "James T.", 
            "id": "sg:person.015430354722.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015430354722.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Widera", 
            "givenName": "Georg", 
            "id": "sg:person.0741425665.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741425665.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "PowderJect Vaccines, Madison, Wisconsin, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "PowderJect Vaccines, Madison, Wisconsin, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Haynes", 
            "givenName": "Joel R.", 
            "id": "sg:person.01054341025.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054341025.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA", 
              "id": "http://www.grid.ac/institutes/grid.419681.3", 
              "name": [
                "Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Purcell", 
            "givenName": "Robert H.", 
            "id": "sg:person.01136664631.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136664631.42"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada", 
              "id": "http://www.grid.ac/institutes/grid.28046.38", 
              "name": [
                "Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada", 
                "Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
                "Department of Microbiology, Immunology and Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, Canada", 
                "School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Davis", 
            "givenName": "Heather L.", 
            "id": "sg:person.01342320235.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342320235.44"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/356152a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023052619", 
              "https://doi.org/10.1038/356152a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3300380", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007732450", 
              "https://doi.org/10.1038/sj.gt.3300380"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1096-1122", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052270183", 
              "https://doi.org/10.1038/nm1096-1122"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0297-167", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042860966", 
              "https://doi.org/10.1038/nbt0297-167"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/386410a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041946870", 
              "https://doi.org/10.1038/386410a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0498-397", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027672674", 
              "https://doi.org/10.1038/nm0498-397"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/374546a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034049921", 
              "https://doi.org/10.1038/374546a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm0597-526", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030499063", 
              "https://doi.org/10.1038/nm0597-526"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03401734", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083229498", 
              "https://doi.org/10.1007/bf03401734"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1999-05-01", 
        "datePublishedReg": "1999-05-01", 
        "description": "BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 \u00b5g) was compared to ID and IM (100 \u00b5g) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 \u00b5g at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 \u00b5g by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/bf03402065", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1113628", 
            "issn": [
              "1076-1551", 
              "1528-3658"
            ], 
            "name": "Molecular Medicine", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "5"
          }
        ], 
        "keywords": [
          "non-human primates", 
          "immune response", 
          "gene gun", 
          "significant titers", 
          "mixed IgG1/IgG2a", 
          "hepatitis B surface antigen", 
          "BALB/c mice", 
          "anti-HBs values", 
          "anti-HBs titers", 
          "T lymphocyte activity", 
          "IgG1/IgG2a", 
          "influences immune responses", 
          "DNA-based immunization", 
          "B surface antigen", 
          "plasmid DNA vaccine", 
          "HBsAg-specific antibodies", 
          "plasma of mice", 
          "non-injected routes", 
          "method of delivery", 
          "IgG2a responses", 
          "lymphocyte activity", 
          "immunization schedule", 
          "single immunization", 
          "IM delivery", 
          "DNA vaccine", 
          "c mice", 
          "IM injection", 
          "optimal dose", 
          "surface antigen", 
          "IgG1 antibodies", 
          "low titers", 
          "high titers", 
          "rhesus monkeys", 
          "BackgroundIn spite", 
          "mice", 
          "immunization", 
          "different doses", 
          "titers", 
          "Additional studies", 
          "One study", 
          "weeks", 
          "monkeys", 
          "high levels", 
          "antibodies", 
          "HBsAg", 
          "injection", 
          "longer intervals", 
          "serum", 
          "HBs", 
          "primates", 
          "delivery", 
          "second study", 
          "response", 
          "IM", 
          "humans", 
          "IgG2a", 
          "vaccine", 
          "IgG1", 
          "antigen", 
          "levels", 
          "study", 
          "CTL", 
          "doses", 
          "administration", 
          "dose", 
          "MethodsEight", 
          "different routes", 
          "skin", 
          "second experiment", 
          "plasmid DNA", 
          "boost", 
          "first experiment", 
          "time", 
          "interval", 
          "later times", 
          "schedule", 
          "plasma", 
          "activity", 
          "cases", 
          "ID", 
          "number", 
          "route", 
          "results", 
          "plasmid", 
          "large number", 
          "IPER", 
          "DNA", 
          "spite", 
          "ability", 
          "SL", 
          "same time", 
          "values", 
          "number of routes", 
          "method", 
          "materials", 
          "vector", 
          "experiments", 
          "nature", 
          "species", 
          "strength", 
          "VW", 
          "gun", 
          "hierarchy"
        ], 
        "name": "Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates", 
        "pagination": "287-300", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1074485462"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/bf03402065"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "10390545"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/bf03402065", 
          "https://app.dimensions.ai/details/publication/pub.1074485462"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:23", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_337.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/bf03402065"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03402065'


     

    This table displays all metadata directly associated to this object as RDF triples.

    366 TRIPLES      21 PREDICATES      158 URIs      139 LITERALS      26 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/bf03402065 schema:about N02c8fa8b975941a9b473e940804b8ad6
    2 N08e78966cf9142fba1a872b7bb031376
    3 N1ef055468d794a6698dbaac263ea46a3
    4 N2099a6adf093450d816ae55fa6051073
    5 N2c23b23e0a3c41cd8e5cc8fad372c0ce
    6 N3560ddcda483442aaca0598841813349
    7 N362d01fc917d40b38329465b0032fda4
    8 N367ffad514594b738b066fa7f2599cca
    9 N723b018a813f4dc589ade5719633d62e
    10 N8541ffb4a7ac4dcfa1317ae0b667423e
    11 Nae56d6c787594f46a28f21ff17d4b0a2
    12 Nb863cba0e2f7480684e3359a0086de1a
    13 Nbb5e1312e7e7473a874e36899d4f3a28
    14 Nc11033d95b1340d6b1d5b4595d5693ef
    15 Nc8ce789823a9488d9f00ff628ec708ab
    16 Ndefabf9f134d47c1bcb35833d1afdd16
    17 Ne4bda56695494d96b8331471191e1986
    18 Ne7f45ebb35cd4c879f149f8bacac7da6
    19 Nfd7472e5ba8c4455a5d54a3cc5c879a9
    20 anzsrc-for:03
    21 anzsrc-for:0304
    22 anzsrc-for:06
    23 anzsrc-for:0601
    24 schema:author N99581bf160f24dafb2cbb9578f024c9c
    25 schema:citation sg:pub.10.1007/bf03401734
    26 sg:pub.10.1038/356152a0
    27 sg:pub.10.1038/374546a0
    28 sg:pub.10.1038/386410a0
    29 sg:pub.10.1038/nbt0297-167
    30 sg:pub.10.1038/nm0498-397
    31 sg:pub.10.1038/nm0597-526
    32 sg:pub.10.1038/nm1096-1122
    33 sg:pub.10.1038/sj.gt.3300380
    34 schema:datePublished 1999-05-01
    35 schema:datePublishedReg 1999-05-01
    36 schema:description BackgroundIn spite of the large number of studies that have evaluated DNA-based immunization, few have directly compared the immune responses generated by different routes of immunization, particularly in non-human primates. Here we examine the ability of a hepatitis B surface antigen (HBsAg)-encoding plasmid to induce immune responses in mice and non-human primates (rhesus monkeys: Macaca mulatta) after delivery by a number of routes.Materials and MethodsEight different injected [intraperitoneal (IP), intradermal (ID), intravenous (IV), intramuscular (IM), intraperineal (IPER), subcutaneous (SC), sublingual (SL), vaginal wall (VW)] and six non-injected [intranasal inhalation (INH), intranasal instillation (INS), intrarectal (IR), intravaginal (IVAG), ocular (Oc), oral feeding (oral)] routes and the gene gun (GG) were used to deliver HBsAg-expressing plasmid DNA to BALB/c mice. Sera were assessed for HBsAg-specific antibodies (anti-HBs, IgG, IgG1, IgG2a) and cytotoxic T lymphocyte (CTL) activity measured. Three of the most commonly used routes (IM, ID, GG) were compared in rhesus monkeys, also using HBsAg-expressing vectors. Monkeys were immunized with short (0-, 4- and 8-week) or long (0-, 12- and 24-week) intervals between boosts, and in the case of GG, also with different doses, and their sera were assessed for anti-HBs.ResultsIn one study, anti-HBs were detected in plasma of mice treated by five of eight of the injected and none of the six noninjected routes. The highest levels of anti-HBs were induced by IM and IV injections, although significant titers were also obtained with SL and ID. Each of these routes also induced CTL, as did IPER and VW and one noninjected route (INH) that failed to induce antibodies. In a second study, GG (1.6 µg) was compared to ID and IM (100 µg) delivery. Significant titers were obtained by all routes after only one boost, with the highest levels detected by IM. Delivery to the skin by GG induced exclusively IgG1 antibodies (Th2-like) at 4 weeks and only very low IgG2a levels at later times; ID-immunized mice had predominantly IgG1 at 4 weeks and this changed to mixed IgG1/IgG2a over time. Responses with IM injection (in the leg or tongue) were predominantly IgG2a (Th1-like) at all times. IV injection gave mixed IgG1/IgG2a responses. In monkeys, in the first experiment, 1 mg DNA IM or ID at 0, 4, and 8 weeks gave equivalent anti-HB titers and 0.4 µg at the same times by GG induced lower titers. In the second experiment, 1 mg DNA IM or ID, or 3.2 µg by GG, at 0, 12, and 24 weeks, gave anti-HB values in the hierarchy of GG > IM > ID. Furthermore, high titers were retained after a single immunization in mice but fell off over time in the monkeys, even after boost.ConclusionsRoute of administration of plasmid DNA vaccines influences the strength and nature of immune responses in mice and non-human primates. However, the results in mice were not always predictive of those in monkeys and this is likely true for humans as well. Optimal dose and immunization schedule will most likely vary between species. It is not clear whether results in non-human primates will be predictive of results in humans, thus additional studies are required.
    37 schema:genre article
    38 schema:isAccessibleForFree true
    39 schema:isPartOf N16182d2898254b83981d02f372d55dc1
    40 Nf85bca83489b4407aa671f09f8750e7c
    41 sg:journal.1113628
    42 schema:keywords Additional studies
    43 B surface antigen
    44 BALB/c mice
    45 BackgroundIn spite
    46 CTL
    47 DNA
    48 DNA vaccine
    49 DNA-based immunization
    50 HBs
    51 HBsAg
    52 HBsAg-specific antibodies
    53 ID
    54 IM
    55 IM delivery
    56 IM injection
    57 IPER
    58 IgG1
    59 IgG1 antibodies
    60 IgG1/IgG2a
    61 IgG2a
    62 IgG2a responses
    63 MethodsEight
    64 One study
    65 SL
    66 T lymphocyte activity
    67 VW
    68 ability
    69 activity
    70 administration
    71 anti-HBs titers
    72 anti-HBs values
    73 antibodies
    74 antigen
    75 boost
    76 c mice
    77 cases
    78 delivery
    79 different doses
    80 different routes
    81 dose
    82 doses
    83 experiments
    84 first experiment
    85 gene gun
    86 gun
    87 hepatitis B surface antigen
    88 hierarchy
    89 high levels
    90 high titers
    91 humans
    92 immune response
    93 immunization
    94 immunization schedule
    95 influences immune responses
    96 injection
    97 interval
    98 large number
    99 later times
    100 levels
    101 longer intervals
    102 low titers
    103 lymphocyte activity
    104 materials
    105 method
    106 method of delivery
    107 mice
    108 mixed IgG1/IgG2a
    109 monkeys
    110 nature
    111 non-human primates
    112 non-injected routes
    113 number
    114 number of routes
    115 optimal dose
    116 plasma
    117 plasma of mice
    118 plasmid
    119 plasmid DNA
    120 plasmid DNA vaccine
    121 primates
    122 response
    123 results
    124 rhesus monkeys
    125 route
    126 same time
    127 schedule
    128 second experiment
    129 second study
    130 serum
    131 significant titers
    132 single immunization
    133 skin
    134 species
    135 spite
    136 strength
    137 study
    138 surface antigen
    139 time
    140 titers
    141 vaccine
    142 values
    143 vector
    144 weeks
    145 schema:name Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates
    146 schema:pagination 287-300
    147 schema:productId N40f08f339455419b98d43e9c660d780a
    148 Naf14b1bb03564b4a89edcdef84990be6
    149 Nbcf2d78b96e644769c5863d8099fc9fe
    150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074485462
    151 https://doi.org/10.1007/bf03402065
    152 schema:sdDatePublished 2022-12-01T06:23
    153 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    154 schema:sdPublisher N5697f463f2014c6892e56c7254fb365e
    155 schema:url https://doi.org/10.1007/bf03402065
    156 sgo:license sg:explorer/license/
    157 sgo:sdDataset articles
    158 rdf:type schema:ScholarlyArticle
    159 N0274b63ce3be47908380e3681fd953ed rdf:first sg:person.01342320235.44
    160 rdf:rest rdf:nil
    161 N02c8fa8b975941a9b473e940804b8ad6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Predictive Value of Tests
    163 rdf:type schema:DefinedTerm
    164 N08e78966cf9142fba1a872b7bb031376 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Macaca mulatta
    166 rdf:type schema:DefinedTerm
    167 N16182d2898254b83981d02f372d55dc1 schema:issueNumber 5
    168 rdf:type schema:PublicationIssue
    169 N1ef055468d794a6698dbaac263ea46a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Hepatitis B Surface Antigens
    171 rdf:type schema:DefinedTerm
    172 N2099a6adf093450d816ae55fa6051073 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Animals
    174 rdf:type schema:DefinedTerm
    175 N2c23b23e0a3c41cd8e5cc8fad372c0ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Vaccines, DNA
    177 rdf:type schema:DefinedTerm
    178 N3560ddcda483442aaca0598841813349 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Time Factors
    180 rdf:type schema:DefinedTerm
    181 N361feee21f7543fc96ac22d206432ed1 rdf:first sg:person.014200716477.00
    182 rdf:rest Nb476394886f044b687cf52d7c712b48b
    183 N362d01fc917d40b38329465b0032fda4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    184 schema:name Female
    185 rdf:type schema:DefinedTerm
    186 N367ffad514594b738b066fa7f2599cca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Administration, Cutaneous
    188 rdf:type schema:DefinedTerm
    189 N379527b833f84633aced3c54afcd339b rdf:first sg:person.01350227236.96
    190 rdf:rest N711fd30b4aee48ffa1c797b473939b4a
    191 N40f08f339455419b98d43e9c660d780a schema:name doi
    192 schema:value 10.1007/bf03402065
    193 rdf:type schema:PropertyValue
    194 N5697f463f2014c6892e56c7254fb365e schema:name Springer Nature - SN SciGraph project
    195 rdf:type schema:Organization
    196 N711fd30b4aee48ffa1c797b473939b4a rdf:first sg:person.01362275224.11
    197 rdf:rest N891750c166824a96ad59eebfc53fd3d8
    198 N723b018a813f4dc589ade5719633d62e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Mice
    200 rdf:type schema:DefinedTerm
    201 N785f6676d21845fd813039c17a36000a rdf:first sg:person.01054341025.16
    202 rdf:rest Ne29b28dab0a54784b573fdbb2fb32b59
    203 N7c454cd376fd424c85b9b5300cce598c rdf:first sg:person.0741425665.18
    204 rdf:rest N785f6676d21845fd813039c17a36000a
    205 N8541ffb4a7ac4dcfa1317ae0b667423e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name T-Lymphocytes, Cytotoxic
    207 rdf:type schema:DefinedTerm
    208 N891750c166824a96ad59eebfc53fd3d8 rdf:first sg:person.015430354722.02
    209 rdf:rest N7c454cd376fd424c85b9b5300cce598c
    210 N99581bf160f24dafb2cbb9578f024c9c rdf:first sg:person.01337224357.57
    211 rdf:rest N361feee21f7543fc96ac22d206432ed1
    212 Nae56d6c787594f46a28f21ff17d4b0a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Immunity, Cellular
    214 rdf:type schema:DefinedTerm
    215 Naf14b1bb03564b4a89edcdef84990be6 schema:name pubmed_id
    216 schema:value 10390545
    217 rdf:type schema:PropertyValue
    218 Nb476394886f044b687cf52d7c712b48b rdf:first sg:person.01040316565.93
    219 rdf:rest N379527b833f84633aced3c54afcd339b
    220 Nb863cba0e2f7480684e3359a0086de1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Hepatitis B Vaccines
    222 rdf:type schema:DefinedTerm
    223 Nbb5e1312e7e7473a874e36899d4f3a28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    224 schema:name Male
    225 rdf:type schema:DefinedTerm
    226 Nbcf2d78b96e644769c5863d8099fc9fe schema:name dimensions_id
    227 schema:value pub.1074485462
    228 rdf:type schema:PropertyValue
    229 Nc11033d95b1340d6b1d5b4595d5693ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    230 schema:name Administration, Oral
    231 rdf:type schema:DefinedTerm
    232 Nc8ce789823a9488d9f00ff628ec708ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    233 schema:name Antibody Formation
    234 rdf:type schema:DefinedTerm
    235 Ndefabf9f134d47c1bcb35833d1afdd16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    236 schema:name Injections, Intravenous
    237 rdf:type schema:DefinedTerm
    238 Ne29b28dab0a54784b573fdbb2fb32b59 rdf:first sg:person.01136664631.42
    239 rdf:rest N0274b63ce3be47908380e3681fd953ed
    240 Ne4bda56695494d96b8331471191e1986 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    241 schema:name Mice, Inbred BALB C
    242 rdf:type schema:DefinedTerm
    243 Ne7f45ebb35cd4c879f149f8bacac7da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    244 schema:name Injections, Intramuscular
    245 rdf:type schema:DefinedTerm
    246 Nf85bca83489b4407aa671f09f8750e7c schema:volumeNumber 5
    247 rdf:type schema:PublicationVolume
    248 Nfd7472e5ba8c4455a5d54a3cc5c879a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    249 schema:name Administration, Intranasal
    250 rdf:type schema:DefinedTerm
    251 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
    252 schema:name Chemical Sciences
    253 rdf:type schema:DefinedTerm
    254 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
    255 schema:name Medicinal and Biomolecular Chemistry
    256 rdf:type schema:DefinedTerm
    257 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    258 schema:name Biological Sciences
    259 rdf:type schema:DefinedTerm
    260 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    261 schema:name Biochemistry and Cell Biology
    262 rdf:type schema:DefinedTerm
    263 sg:journal.1113628 schema:issn 1076-1551
    264 1528-3658
    265 schema:name Molecular Medicine
    266 schema:publisher Springer Nature
    267 rdf:type schema:Periodical
    268 sg:person.01040316565.93 schema:affiliation grid-institutes:grid.415913.b
    269 schema:familyName Gramzinski
    270 schema:givenName Robert A.
    271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040316565.93
    272 rdf:type schema:Person
    273 sg:person.01054341025.16 schema:affiliation grid-institutes:None
    274 schema:familyName Haynes
    275 schema:givenName Joel R.
    276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054341025.16
    277 rdf:type schema:Person
    278 sg:person.01136664631.42 schema:affiliation grid-institutes:grid.419681.3
    279 schema:familyName Purcell
    280 schema:givenName Robert H.
    281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136664631.42
    282 rdf:type schema:Person
    283 sg:person.01337224357.57 schema:affiliation grid-institutes:grid.28046.38
    284 schema:familyName McCluskie
    285 schema:givenName Michael J.
    286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337224357.57
    287 rdf:type schema:Person
    288 sg:person.01342320235.44 schema:affiliation grid-institutes:grid.28046.38
    289 schema:familyName Davis
    290 schema:givenName Heather L.
    291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342320235.44
    292 rdf:type schema:Person
    293 sg:person.01350227236.96 schema:affiliation grid-institutes:grid.168645.8
    294 schema:familyName Robinson
    295 schema:givenName Harriet L.
    296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350227236.96
    297 rdf:type schema:Person
    298 sg:person.01362275224.11 schema:affiliation grid-institutes:grid.168645.8
    299 schema:familyName Santoro
    300 schema:givenName Joseph C.
    301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362275224.11
    302 rdf:type schema:Person
    303 sg:person.014200716477.00 schema:affiliation grid-institutes:grid.412687.e
    304 schema:familyName Millan
    305 schema:givenName Cynthia L. Brazolot
    306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014200716477.00
    307 rdf:type schema:Person
    308 sg:person.015430354722.02 schema:affiliation grid-institutes:None
    309 schema:familyName Fuller
    310 schema:givenName James T.
    311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015430354722.02
    312 rdf:type schema:Person
    313 sg:person.0741425665.18 schema:affiliation grid-institutes:None
    314 schema:familyName Widera
    315 schema:givenName Georg
    316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741425665.18
    317 rdf:type schema:Person
    318 sg:pub.10.1007/bf03401734 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083229498
    319 https://doi.org/10.1007/bf03401734
    320 rdf:type schema:CreativeWork
    321 sg:pub.10.1038/356152a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023052619
    322 https://doi.org/10.1038/356152a0
    323 rdf:type schema:CreativeWork
    324 sg:pub.10.1038/374546a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034049921
    325 https://doi.org/10.1038/374546a0
    326 rdf:type schema:CreativeWork
    327 sg:pub.10.1038/386410a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041946870
    328 https://doi.org/10.1038/386410a0
    329 rdf:type schema:CreativeWork
    330 sg:pub.10.1038/nbt0297-167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042860966
    331 https://doi.org/10.1038/nbt0297-167
    332 rdf:type schema:CreativeWork
    333 sg:pub.10.1038/nm0498-397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027672674
    334 https://doi.org/10.1038/nm0498-397
    335 rdf:type schema:CreativeWork
    336 sg:pub.10.1038/nm0597-526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030499063
    337 https://doi.org/10.1038/nm0597-526
    338 rdf:type schema:CreativeWork
    339 sg:pub.10.1038/nm1096-1122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052270183
    340 https://doi.org/10.1038/nm1096-1122
    341 rdf:type schema:CreativeWork
    342 sg:pub.10.1038/sj.gt.3300380 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007732450
    343 https://doi.org/10.1038/sj.gt.3300380
    344 rdf:type schema:CreativeWork
    345 grid-institutes:None schema:alternateName PowderJect Vaccines, Madison, Wisconsin, USA
    346 schema:name PowderJect Vaccines, Madison, Wisconsin, USA
    347 rdf:type schema:Organization
    348 grid-institutes:grid.168645.8 schema:alternateName Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    349 schema:name Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    350 rdf:type schema:Organization
    351 grid-institutes:grid.28046.38 schema:alternateName Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    352 School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    353 schema:name Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    354 Department of Microbiology, Immunology and Biochemistry, Faculty of Medicine, University of Ottawa, Ottawa, Canada
    355 Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    356 School of Rehabilitation Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    357 rdf:type schema:Organization
    358 grid-institutes:grid.412687.e schema:alternateName Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    359 schema:name Loeb Health Research Institute at the Ottawa Hospital, 725 Parkdale Avenue, K1Y 4E9, Ottawa, Canada
    360 rdf:type schema:Organization
    361 grid-institutes:grid.415913.b schema:alternateName Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA
    362 schema:name Malaria Program, Naval Medical Research Institute, Rockville, Maryland, USA
    363 rdf:type schema:Organization
    364 grid-institutes:grid.419681.3 schema:alternateName Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    365 schema:name Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    366 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...